Editorial: Expert opinions and perspectives in complement: 2022

Front Immunol. 2023 Jul 12:14:1248299. doi: 10.3389/fimmu.2023.1248299. eCollection 2023.

Marcin Okrój¹, Nicolas S Merle², Jinhua Lu^{3

4}

¹ Intercollegiate Faculty of Biotechnology of University of Gdańsk and Medical University of Gdańsk, Gdańsk, Poland.
² Complement and Inflammation Research Section (CIRS), National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, United States.
³ Department of Microbiology and Immunology, Young Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
⁴ Immunology Translational Research Programme, Young Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

No abstract available

Keywords: COVID-19; SLE; cardiovascular; complement inhibitors; neuroinflammation; nucleolin; smoking.

Publication types

This work is supported by the Singapore National Medical Research Council Open-funding Individual Research Grants (NMRC/OFIRG/0013/2016; MOH-000958).